Company intelligence / Profile preview

Magnolia Neurosciences

New York, New York, United Statesbusinesswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Magnolia Neurosciences develops novel small molecule neuroprotective therapies targeting CNS diseases and neuronal injury. Their lead programs have shown promising preclinical results in models of chemotherapy-induced neuropathy and cognitive impairment. The company aims to rapidly achieve clinical proof-of-concept for these therapies addressing significant unmet needs in neurology. No public data yet on human trial outcomes or late-stage development.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

IACS-8287

Pre-clinical

Indications: Chemotherapy-induced peripheral neuropathy, Chemotherapy-induced cognitive impairment

Partnerships

University of Texas MD Anderson Cancer Center (co-founder/launch partner)

Beyond the preview

Go deeper on Magnolia Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magnolia Neurosciences.

Explore the full profile